Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (Delaware) covers events occurring on December 1, 2015, and December 2, 2015. The report details the election of a new director and associated compensatory arrangements.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data provided relates to a specific transaction:
- Capital Raise: On November 18, 2015, the Company received an aggregate purchase price of $500,000.
- Transaction Components: The purchase included 125,000 shares of common stock and a five-year warrant to purchase 125,000 shares at an exercise price of $5.00 per share.
- Stock Option Grant: The new director was granted an option to purchase 15,000 shares at an exercise price of $4.40 per share.
Material Changes
The primary material change reported is the expansion of the Board of Directors and the issuance of equity instruments:
- Director Election: John M. Desmarais was elected to the Board of Directors on December 1, 2015.
- Compensatory Arrangement: Concurrent with his election, Mr. Desmarais received a stock option grant vesting over three years (5,000 shares annually) with a ten-year exercise period.
- Corporate Governance Resolution: The Board adopted a resolution granting Mr. Desmarais the right to pursue corporate opportunities, subject to exceptions.
Guidance, Risks, and Contingencies
The filing outlines specific contingencies tied to the November 18, 2015, investment by Mr. Desmarais:
- Repurchase Rights: If the Company failed to elect Mr. Desmarais to the Board within 30 days of the purchase closing, he had the right to require the Company to repurchase the shares at $4.00 per share.
- Resolution Contingency: A similar repurchase right exists if the Board fails to adopt the corporate opportunities resolution or if it rescinds, revokes, or modifies such resolution.
- Repurchase Price Formula: In the event of a repurchase triggered by the modification of the resolution, the price per share is the greater of $4.00 or the average closing price of the common stock on the five trading days immediately preceding the repurchase date.
Investor Verification Checklist
- Verify the current status of the Board of Directors and committee assignments for John M. Desmarais.
- Confirm the vesting schedule and exercise status of the 15,000 share option granted to Mr. Desmarais.
- Review the specific exceptions outlined in the Board resolution regarding Mr. Desmarais's right to pursue corporate opportunities.
- Check subsequent filings to ensure no repurchase rights were triggered under the terms of the November 18, 2015, agreement.